Acetic Acid

Acetic Acid

SCHEMBL8970517

CC(=O)O.CCc1ccc(NS(=O)(=O)c2ccc(Cl)cc2)cc1

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GHSR known ✓ Q92847 1/20 0.55
UCHL1 P09936 1/20 0.66
CES1 P23141 1/20 0.63
ALDH1A1 P00352 3/20 0.59
HDAC3 O15379 2/20 0.59
HDAC4 P56524 2/20 0.59
HDAC1 Q13547 2/20 0.59
HDAC7 Q8WUI4 2/20 0.59
HDAC2 Q92769 2/20 0.59
HDAC10 Q969S8 2/20 0.59
HDAC11 Q96DB2 2/20 0.59
HDAC8 Q9BY41 2/20 0.59
HDAC6 Q9UBN7 2/20 0.59
HDAC9 Q9UKV0 2/20 0.59
HDAC5 Q9UQL6 2/20 0.59
KMT2A Q03164 2/20 0.58
L3MBTL1 Q9Y468 1/20 0.58
HTT P42858 2/20 0.57
MAPT P10636 2/20 0.56
TP53 P04637 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19234560 0.93 UCHL1 (0.76) UCHL1CES1ALDH1A1KMT2AL3MBTL1
SCHEMBL6553107 0.93 UCHL1 (0.76) UCHL1CES1ALDH1A1KMT2AL3MBTL1
SCHEMBL24324833 0.81 CES1 (0.69) UCHL1CES1ALDH1A1HTTMAPT
SCHEMBL6302353 0.80 UCHL1 (0.76) UCHL1ALDH1A1KMT2AL3MBTL1HTT
SCHEMBL12058761 0.80 UCHL1 (0.75) UCHL1ALDH1A1KMT2AL3MBTL1MAPT
SCHEMBL13185624 0.80 UCHL1 (0.75) UCHL1ALDH1A1HDAC4HDAC1HDAC8
SCHEMBL31702460 0.80 CES1 (0.58) CES1ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL5608211 0.80 CES1 (0.58) CES1ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL27734527 0.80 CES1 (0.58) CES1ALDH1A1HDAC3HDAC4HDAC1
SCHEMBL19234895 0.80 CES1 (0.58) CES1ALDH1A1HDAC3HDAC4HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5545671-A ADMINISTERING A CYCLODEXTRIN CLATHRATE OF EPTALOPROST OR CICAPROST SCHERING AKTIENGESELLSCHAFT (DE) 1996-08-13 US disclosed
US-5523321-A Prostacyclins, their analogs or prostaglandins and thromboxane antagonists for treatment of thrombotic and thromboembolic syndromes SCHERING AKTIENGESELLESCHAFT (DE) 1996-06-04 US disclosed
WO-1991004739-A1 USE OF PROSTACYCLIN DERIVATIVES AGAINST METASTASES SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) 1991-04-18 WO disclosed
EP-0421562-A2 Use of prostacyclin analogs against metastases SCHERING AKTIENGESELLSCHAFT (DE) 1991-04-10 EP disclosed